Repository

Opening Session

	Opening video
	Welcome by Chairs P. Lampertico and H. Wedemeyer

WHO session | Hepatitis Delta: making a difference in low- and middle-income countries

	Updated WHO HBV guidelines and recommendations for testing and diagnosis for HDV N. Luhmann
	Diagnostics for HDV: what we have and what we need for improving diagnosis in low- and-middle income countries I. Chemin
	Hepatitis Delta epidemiology and experiences with HDV diagnosis and reflex testing in Uzbekistan E. Musabaev
	HDV diagnosis and treatment in Pakistan and the way forward for LMICs S.S. Hamid

Session 1 | Virology and Pathogenesis

	Virology: the latest insights S. Urban
	Pathogenesis: insights from liver biopsies L. Allweiss
	New HBV biomarkers: any role in HDV? B. Testoni
	Oral presentationIntegrative transcriptomics and epigenomics reveals a viral footprint of chronic HDV infection in HBV co-infected chimeric livers J. Lupberger

Session 2 | Diagnosis, Staging, HCC risk and antiviral therapy

	HDV-RNA assays: performances and clinical challenges M.P. Anolli
	Fibroscan and other non-invasive markers L. Sandmann
	PegIFN+NUC: predictors of response M. Brunetto
	Oral presentation Hepatitis delta virus (HDV) replication through HBV integrants in HCC recurrence after liver transplantation L. Di Marco

Session 3 | Current and new antiviral treatments I

	Bulevirtide mono and combo in clinical trials H. Wedemeyer
	Bulevirtide in EU: SAVE-D study update E. Degasperi
	Bulevirtide in France: multicenter study update H. Fontaine
	Bulevirtide for decompensated cirrhosis M. Jachs
	Oral presentationEfficacy and safety of BLV monotherapy for chronic hepatitis delta: post treatment results through 24 weeks after the end of treatment from an interim analysis of a randomized Phase 3 study MYR301 S. Aleman

Session 4 | Current and new antiviral treatments II

	Bulevirtide in HIV coinfected patients G. D’Offizi
	Can we stop Bulevirtide? Lessons learned from viral kinetics modellingH. Dahari
	What have we learned from the Lonafarnib and pegIFN lambda trials? T. Asselah
	New antivirals for HDV, phase II studies K. Agarwal
	What can we learn from HBV trials for HDV cure? M. Levrero
	Oral presentationEfficacy and safety of tobevibart (VIR-3434) alone or in combination with elebsiran (VIR-2218) in participants with chronic hepatitis delta virus infection: preliminary results from the Phase 2 SOLSTICE trial in non-cirrhotic and compensated cirrhotic participants T. Asselah

With the unconditional support of

View and download the Speakers' slides, divided by sessions,...